- Executive Summary
- 1. Introduction
- 1.1 Resume of Study Objectives and Scope
- 1.2 Research Plan and Progress to Date
- 1.3 Structure of the Final Report
- 2. EMCDDA Mission & Coherence with Drugs Policy Framework
- 2.1 Role of the EMCDDA
- 2.2 EMCDDA Intervention Logic & 2007-12 Work Programmes
- 2.3 Coherence with Regulatory Framework and EU Policies
- 2.4 Coherence with EMCDDA Stakeholder Priorities
- 2.5 Conclusions - Mission and Coherence
- 3. Assessment of EMCDDA Outputs & Activities
- 3.1 Overall Progress towards EMCDDA Objectives
- 3.2 Demand side and Key Epidemiological Indicators
- 3.3 Supply Side of the Drug Problem
- 3.4 New Psychoactive Substances and the Early Warning System
- 3.5 EMCDDA and Health and Social Responses
- 3.6 EMCDDA and National Policies to Combat the Drugs Problem
- 3.7 Scientific Publications and other Outputs
- 3.8 2007 Evaluation and follow Up Actions
- 3.9 Conclusions – EMCDDA Activities and Outputs
- 4. Reaching Key Stakeholders and Target Groups
- 4.1 EMCDDA Key Stakeholders
- 4.2 Cooperation with International Partners & Third Countries
- 4.3 EMCDDA Communications Strategy
- 4.4 Effectiveness in Reaching Target Groups
- 4.5 Conclusions – Key Stakeholders and Target Groups
- 5. EMCDDA Organisation and Governance
- 5.1 Overview - EMCDDA Organisation
- 5.2 Role of the EMCDDA Statutory Bodies
- 5.3 EMCDDA Units
- 5.4 EMCDDA’s Human and Financial Resources
- 5.5 Role of the REITOX Network
- 5.6 Conclusions – EMCDDA Organisation and Governance
- 6. Conclusions and Recommendations
- 5.1 Overall Conclusions
- 5.2 EMCDDA Activities and Outputs
- 5.3 Reaching EMCDDA Target Groups
- 5.4 EMCDDA Organisation and Governance
- APPENDICES (SEPARATE DOCUMENT)A. List of Interviews
- B. Assessment of EMCDDA Outputs
- C. Assessment of EMCDDA Work Programmes
- D. Comparison with Other EU Agencies
- E. Analysis of Survey Data
Persistent link: https://www.econbiz.de/10010528001